Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

By A. Regev, M. Berho, L. Jeffers, C. Milikowski, E. Molina, N. Pyrsopoulos, Zheng Feng, K. Reddy, E. Schiff. American Journal of Gastroenterology, 2002

2,200 citations recorded by the source corpus.

Subfields: Epidemiology, Physiology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/7d6bbfb598baaa784d9224798e325c0751b60d96

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Physiology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study (2005, background): “liver biopsy in assessing fibrosis may be questioned because of sampling error and interobserver variability that may lead to understaging of cirrhosis (6-9).”
FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest (2007, methodology): “We reviewed our computerized files of HCV-infected patients attending our unit and selected all the cases corresponding to the following criteria: (1) anti HCV- and HCV-RNA–positive; (2) LB prior to any antiviral therapy; (3) laboratory assessments allowing FIB-4 calculation (AST, ALT, platelet coun”
Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, background): “, bleeding) are problematic.(227-231) Additionally, most clinicians and patients (or their parents) prefer noninvasive alternatives to determine the presence or absence of cirrhosis, particularly in the pediatric population.”
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C (2003, neutral): “00 126 (66) 123 (75) 3 (11) 89 75 38 98 1.”
Evolving challenges in hepatic fibrosis (2010, background): “Although most chronic liver diseases are relatively homogeneous, the modest variability from region to region is sufficient to yield discordance in fibrosis staging in at least one-third of biopsy samples from patients with hepatitis”
Evaluation of Liver Fibrosis: A Concise Review (2004, background): “For instance, in a recent study, biopsies taken at laparoscopy from both the right and the left lobes of the liver were compared (23).”
Quantifying hepatic shear modulus in vivo using acoustic radiation force. (2008, background): “While core biopsy is considered to be the current gold standard for evaluating liver health, its accuracy is limited by a small sample size, with misdiagnosis in fibrosis staging reported in 20–40% of cases (Ratziu et al., 2005; Regev et al., 2002; Bedossa et al., 2003).”
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Indeed, liver biopsy provides only a very small part of the whole organ and there is a risk that this part might not be representative for the amount of hepatic fibrosis in the whole liver due to heterogeneity in its distribution [9].”
WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. (2015, background): “In addition, sampling error is an intrinsic problem because of the small sample size taken from a heterogeneous organ (Cholongitas et al. 2006), and diagnostic consistency may be influenced by interobserver variability (Maharaj et al. 1986; Bedossa et al. 2003; Regev et al. 2002).”